Right now, you can lock in help with PDFs forever with this lifetime subscription to PDF Converter and Editor, on sale for ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback